Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 417.35 INR 0.85% Market Closed
Market Cap: 193B INR

EV/EBIT
Enterprise Value to EBIT

33.9
Current
25.8
Median
15.8
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
33.9
=
Enterprise Value
210.9B INR
/
EBIT
6.2B INR
EBIT Growth EV/EBIT to Growth
IN
Eris Lifesciences Ltd
NSE:ERIS
Average EV/EBIT: 1 702.7
33.9
30%
1.1
US
Eli Lilly and Co
NYSE:LLY
46.2
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.5
12%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
15.4
16%
1
CH
Roche Holding AG
SIX:ROG
13.4
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
193.6
21%
9.2
CH
Novartis AG
SIX:NOVN
14.6
8%
1.8
US
Merck & Co Inc
NYSE:MRK
10.5
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.1
10%
1.2

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
28.8
2-Years Forward
EV/EBIT
23.5
3-Years Forward
EV/EBIT
19.2